The FAM Regimen for Gastric Cancer: A Progress Report

  • P. S. Schein
  • J. S. Macdonald
  • P. V. Woolley
  • F. P. Smith
  • D. F. Hoth
  • M. Boiron
  • C. Gisselbrecht
  • R. Brunet
  • C. Lagarde
Conference paper
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 76)

Abstract

The FAM regimen for upper gastrointestinal cancer was developed during 1974. It incorporated three anticancer drugs which had demonstrated independent activity against gastric cancer: 5-fluorouracil, adriamycin [2], and mitomycin-C [3]. In an attempt to insure adequate patient tolerance and allow for chronic administration, an intermittent schedule was designed (Table 1). In particular, mitomycin-C was to be administered only once every 2 months because of its then appreciated delayed and cumulative bone marrow toxicity. We have recently reported the criteria for entry into this study, including the strict requirement for followable disease criteria for patient response, as well as the initial response rates and survival curves [1]. This progress report describes the updated results in the treatment of 62 patients with advanced and measurable gastric cancer.

Keywords

Toxicity Adriamycin Chloroethylnitrosourea 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    MacDonald JS, Woolley PV, Smythe T, Ueno W, Hoth D, Schein PS (to be published) 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. CancerGoogle Scholar
  2. 2.
    Moertel CG (1976) Chemotherapy of gastrointestinal cancer. Clin Gastroenterol 5:777PubMedGoogle Scholar
  3. 3.
    Moore GE, Bross IDJ, Ausman R, Nadler S, Jones R, Slack N, Rimm AA (1968) Efficacy of mitomycin-C in 346 patients with advanced cancer. Cancer Chemother Rep 52:641PubMedGoogle Scholar
  4. 4.
    Panettiere FJ, Heibrun L (1979) Experiences with two treatment schedules in the combination chemotherapy of advanced gastric carcinoma. In: Carter S, Crooke S (eds) Mitomycin-C: Current status and new developments. Academic Press, New York San Francisco LondonGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1981

Authors and Affiliations

  • P. S. Schein
    • 1
  • J. S. Macdonald
    • 1
  • P. V. Woolley
    • 1
  • F. P. Smith
    • 1
  • D. F. Hoth
    • 1
  • M. Boiron
    • 1
  • C. Gisselbrecht
    • 1
  • R. Brunet
    • 1
  • C. Lagarde
    • 1
  1. 1.Vincent T. Lombardi Cancer Research CenterGeorgetown University School of MedicineUSA

Personalised recommendations